Identification of a Novel Subtype-Selective α_1B-Adrenoceptor Antagonist.

Area of Science:

• Pharmacology
• Neuroscience
• Medicinal Chemistry

Background:

• Alpha-1 adrenoceptors (α1-ARs) are G protein-coupled receptors activated by adrenaline and noradrenaline.
• Current α1-AR antagonists lack subtype selectivity, limiting their therapeutic use and research applications.
• The α1B-AR subtype is a potential target for cardiovascular and central nervous system disorders, but selective compounds are scarce.

Purpose of the Study:

• To discover and characterize novel subtype-selective α1B-AR antagonists.
• To elucidate the molecular basis for α1B-AR selectivity.
• To identify potential lead compounds for α1B-AR-targeted drug discovery.

Main Methods:

• Discovery of Cpd1, an α1B-AR antagonist, through screening.
• Computational modeling and site-directed mutagenesis to determine the binding site and selectivity mechanism.
• Structure-activity relationship studies to identify Cpd24, a related compound with altered affinity and selectivity.

Main Results:

• Cpd1 demonstrated 10-15 fold selectivity for α1B-AR over α1A-AR and α1D-AR.
• The nonconserved residue V19745.52 and L3146.55 were identified as key to Cpd1's α1B-AR selectivity.
• Cpd24 showed enhanced binding affinity but reduced selectivity compared to Cpd1.

Conclusions:

• Cpd1 is a valuable tool compound for investigating α1B-AR physiology and its role in disease.
• Cpd1 and Cpd24 represent promising starting points for developing novel α1B-AR-selective therapeutics.
• Understanding the structural basis of selectivity facilitates rational drug design for α1-AR subtypes.